2012 Confirmed Speakers Include:

• Sridaran Natesan Ph.D, Scientific Site Head (R&D) & Head, External Innovation and Partnering (US, Northeast), Sanofi
• Chuck Wilson, VP Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research Inc.
• Timothy J. Dolan, Corporate Business Development, Eli Lilly and Company
• Mark Nuttall, VP Business Development, Johnson & Johnson
• Mark Dennish, VP Business Development, Daiichi Sankyo, Inc.
• Karen LaRochelle, Executive Director, Business Development, Bristol-Myers Squibb Company
• Sanjeev Munshi, Ph.D, MBA, Director, Licensing and External Research, Mid-Atlantic & Southeastern US, Merck & Co. Inc.
• Steven Xanthoudakis, Director, Worldwide Licensing & External Research, Merck & Co. Inc.
• Christine Grygon, Head BI Partnering, Boehringer Ingelheim
• Carlos Garrido, Director, Business Development Latin America, AstraZeneca
• John Gustofson, Director, Business Development, AstraZeneca
• Berthold Hinzen, Head of BD & Licensing, Global Medicine, Bayer
• Zafrira Avnur, Ph.D., Head, Global Academic Innovation Partnering, Roche Partnering
• Jeff Wasserstein, SVP Business Development & Strategy, Nycomed US
• Nicole J. Walker, Director, Venture Investments, Abbott Biotech Ventures
• Gwen Melincoff, SVP Business Development, Strategic Investment Group, Shire Pharmaceuticals
• John Sorvillo, Director, Licensing, External R&D, Amgen
• Eric Thomas Olson, Senior Associate, Genzyme Ventures
• Cameron Carvalho, Director of Business Development, Teva Canada
• Allen Downs, Senior Executive Director Licensing and Business Development, Purdue Pharma
• Rick Hoyt, VP Business Development, Covidien
• Syed Kazmi, VP Business Development and Strategic Planning, Ligand Pharmaceuticals, Inc.
• Anthony Recupero, Senior Director of Business Development, Aptalis Pharma
• James Hattersley, VP, Corp. Business Development, Sun Pharmaceutical Industries, Inc.
• Gregory Miller, Head of Business and Corporate Development, Concert Pharmaceuticals, Inc.
• Steven Hutchins, SVP Strategic Business Development, Evotec
• Len Smith, Principal Intellectual Property Counsel, Medicis Pharmaceutical Corporation
• Steven Ertel, SVP Corporate Development, Acceleron Pharma
• Jones W. Bryan, Ph.D., VP Business Development and Licensing, Supernus Pharmaceuticals
• Stephen Ireland, SVP Business Development, Transtech Pharma, Inc.
• Francois Nader, President and CEO, NPS Pharmaceuticals Inc.
• Al Altomari, President and CEO, Agile Therapeutics
• David Snitman, VP Business Development, Array Biopharma
• Casi DeYoung, VP of Business Development, Reata Pharmaceuticals
• Leland Webster, Ph.D., M.B.A., VP Business Development, Tetraphase Pharmaceuticals Inc.
• Sanj Singh, President & CEO, Ade Therapeutics
• Baruch Harris, VP, Strategy and Operations, Enlight Biosciences
• Anand Mehra, Pricipal, Sofinnova Ventures
• Michael Wasserman, Director, H.I.G. Ventures
• George Farmer, Principal, Research Analyst, Life Sciences, Canaccord Genuity Inc.
• Marc Mallandro, Associate Vice Chancellor For Technology Management And Commercialization, University of Pittsburgh